Research programme: peptide therapeutics - Zealand Pharma/UniQuest
Latest Information Update: 28 Mar 2022
At a glance
- Originator UniQuest; Zealand Pharma
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Gastrointestinal-disorders in Australia
- 28 Mar 2022 No recent reports of development identified for research development in Gastrointestinal-disorders in Denmark
- 20 Feb 2018 Zealand Pharma and UniQuest agree to co-develop peptide therapeutics for Gastrointestinal disorders